Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah Hoffe

Showing results (51-60 of 92) with videos related to

Pageof 10
Sort By:
Journal of Surgical Oncology|August 2, 2022
Neoadjuvant rectal score is prognostic for survival: A population-based propensity-matched analysisSamer A Naffouje, Nicholas Manguso, Iman Imanirad, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 30, 2026
CLO26-076: Prognostic Outcomes in Resected Pancreatic Cancer Treated With Neoadjuvant Chemotherapy Alone: Impact of Integrated Pathologic ScoreJin-Ju Lee, Michael Aboujaoude, Adrianna Oraiqat, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 30, 2026
CLO26-076: Prognostic Outcomes in Resected Pancreatic Cancer Treated With Neoadjuvant Chemotherapy Alone: Impact of Integrated Pathologic ScoreJin-Ju Lee, Michael Aboujaoude, Adrianna Oraiqat, et al.
Journal of Gastrointestinal Oncology|December 4, 2018
Using the Albumin-Bilirubin (ALBI) grade as a prognostic marker for radioembolization of hepatocellular carcinomaHoman Mohammadi, Yazan Abuodeh, William Jin, et al.
Journal of Clinical Medicine|November 27, 2024
The Evolving Role of Neoadjuvant Radiation Therapy in Pancreatic AdenocarcinomaJohn Michael Bryant, Justyn Nakashima, Vaseem M Khatri, et al.
Journal of Surgical Oncology|September 24, 2015
The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor responseAaron U Blackham, Binglin Yue, Khaldoun Almhanna, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|September 10, 2021
Adjuvant Chemoradiotherapy in Resected Pancreatic Ductal Adenocarcinoma: Where Does the Benefit Lie? A Nomogram for Risk Stratification and Patient SelectionSamer A Naffouje, Arvind Sabesan, Dae-Won Kim, et al.
Annals of Surgical Oncology|November 3, 2011
Pathologic nonresponders after neoadjuvant chemoradiation for esophageal cancer demonstrate no survival benefit compared with patients treated with primary esophagectomyGeorge W Dittrick, Jill M Weber, Ravi Shridhar, et al.
Annals of Surgical Oncology|February 9, 2010
Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancerKenneth L Meredith, Jill M Weber, Kiran K Turaga, et al.
Clinical and Translational Radiation Oncology|January 31, 2024
Multi-institutional experience of MR-guided stereotactic body radiation therapy for adrenal gland metastasesMatthew Mills, Rupesh Kotecha, Roberto Herrera, et al.
Pageof 10

Showing results (51-60 of 92) with videos related to

Sort By:
Pageof 10
Journal of Surgical Oncology|August 2, 2022
Neoadjuvant rectal score is prognostic for survival: A population-based propensity-matched analysisSamer A Naffouje, Nicholas Manguso, Iman Imanirad, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 30, 2026
CLO26-076: Prognostic Outcomes in Resected Pancreatic Cancer Treated With Neoadjuvant Chemotherapy Alone: Impact of Integrated Pathologic ScoreJin-Ju Lee, Michael Aboujaoude, Adrianna Oraiqat, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 30, 2026
CLO26-076: Prognostic Outcomes in Resected Pancreatic Cancer Treated With Neoadjuvant Chemotherapy Alone: Impact of Integrated Pathologic ScoreJin-Ju Lee, Michael Aboujaoude, Adrianna Oraiqat, et al.
Journal of Gastrointestinal Oncology|December 4, 2018
Using the Albumin-Bilirubin (ALBI) grade as a prognostic marker for radioembolization of hepatocellular carcinomaHoman Mohammadi, Yazan Abuodeh, William Jin, et al.
Journal of Clinical Medicine|November 27, 2024
The Evolving Role of Neoadjuvant Radiation Therapy in Pancreatic AdenocarcinomaJohn Michael Bryant, Justyn Nakashima, Vaseem M Khatri, et al.
Journal of Surgical Oncology|September 24, 2015
The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor responseAaron U Blackham, Binglin Yue, Khaldoun Almhanna, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|September 10, 2021
Adjuvant Chemoradiotherapy in Resected Pancreatic Ductal Adenocarcinoma: Where Does the Benefit Lie? A Nomogram for Risk Stratification and Patient SelectionSamer A Naffouje, Arvind Sabesan, Dae-Won Kim, et al.
Annals of Surgical Oncology|November 3, 2011
Pathologic nonresponders after neoadjuvant chemoradiation for esophageal cancer demonstrate no survival benefit compared with patients treated with primary esophagectomyGeorge W Dittrick, Jill M Weber, Ravi Shridhar, et al.
Annals of Surgical Oncology|February 9, 2010
Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancerKenneth L Meredith, Jill M Weber, Kiran K Turaga, et al.
Clinical and Translational Radiation Oncology|January 31, 2024
Multi-institutional experience of MR-guided stereotactic body radiation therapy for adrenal gland metastasesMatthew Mills, Rupesh Kotecha, Roberto Herrera, et al.
Pageof 10